| India Branded Pharmaceuticals | Chronic therapies including cardiology, CNS, diabetes, dermatology, consumer health products | Strong brand portfolio, wide distribution network, and patient trust in chronic disease management | B2B (hospitals, clinics) and B2C (direct consumers through prescriptions) | Chronic therapy drugs and select consumer health supplements | 6787 | 59 | Primarily from prescription sales in retail pharmacy chains and hospitals | Branded product pricing with competitive market rates and periodic brand expansions | Expanded field force, new product launches, in-licensing deals, consumer health portfolio growth | Vorxarr (Saroglitazar), Kabvie (Vonoprazan), Shelcal Pro Gummies, Ahaglow, Tedibar |
| International Generics (Germany, Brazil, USA, Others) | Generic drugs in cardiovascular, CNS, diabetes; oncology drugs; OTC and tender market supplies | Regulatory approvals, manufacturing capabilities, and market leadership in Indian pharma overseas | B2B, government tenders, pharmacy chains | Specialty generics and newly launched oncology products | 4599 | 40 | Sales to hospitals, pharmacies, and government tenders through generics offerings | Tender-based, competitive pricing with volume-driven revenues | New tender wins, product launches in oncology and diabetes, better conversion, currency normalization | Heumann (Germany), Bio-Pharm (USA), Curatio brands (Philippines/Sri Lanka) |
